Cargando…

The CaMKII phosphorylation site Thr1604 in the Ca(V)1.2 channel is involved in pathological myocardial hypertrophy in rats

Residue Thr1604 in the Ca(V)1.2 channel is a Ca(2+)/calmodulin dependent protein kinase II (CaMKII) phosphorylation site, and its phosphorylation status maintains the basic activity of the channel. However, the role of Ca(V)1.2 phosphorylation at Thr1604 in myocardial hypertrophy is incompletely und...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jingyuan, Wang, Siqi, Zhang, Jie, Liu, Yan, Zheng, Xi, Ding, Fan, Sun, Xuefei, Zhao, Meimi, Hao, Liying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188351/
https://www.ncbi.nlm.nih.gov/pubmed/32290730
http://dx.doi.org/10.1080/19336950.2020.1750189
_version_ 1783527297006960640
author Li, Jingyuan
Wang, Siqi
Zhang, Jie
Liu, Yan
Zheng, Xi
Ding, Fan
Sun, Xuefei
Zhao, Meimi
Hao, Liying
author_facet Li, Jingyuan
Wang, Siqi
Zhang, Jie
Liu, Yan
Zheng, Xi
Ding, Fan
Sun, Xuefei
Zhao, Meimi
Hao, Liying
author_sort Li, Jingyuan
collection PubMed
description Residue Thr1604 in the Ca(V)1.2 channel is a Ca(2+)/calmodulin dependent protein kinase II (CaMKII) phosphorylation site, and its phosphorylation status maintains the basic activity of the channel. However, the role of Ca(V)1.2 phosphorylation at Thr1604 in myocardial hypertrophy is incompletely understood. Isoproterenol (ISO) was used to induce cardiomyocyte hypertrophy, and autocamtide-2-related inhibitory peptide (AIP) was added as a treatment. Rats in a myocardial hypertrophy development model were subcutaneously injected with ISO for two or three weeks. The heart and left ventricle weights, each of which were normalized to the body weight and cross-sectional area of the myocardial cells, were used to describe the degree of hypertrophy. Protein expression levels were detected by western blotting. CaMKII-induced Ca(V)1.2 (Thr1604) phosphorylation (p-Ca(V)1.2) was assayed by coimmunoprecipitation. The results showed that CaMKII, HDAC, MEF2 C, and atrial natriuretic peptide (ANP) expression was increased in the ISO group and downregulated by AIP treatment in vitro. There was no difference in the expression of these proteins between the ISO 2-week group and the ISO 3-week group in vivo. Ca(V)1.2 channel expression did not change, but p-Ca(V)1.2 expression was increased after ISO stimulation and decreased by AIP. In the rat model, p-Ca(V)1.2 levels and CaMKII activity were much higher in the ISO 3-week group than in the ISO 2-week group. CaMKII-induced Ca(V)1.2 channel phosphorylation at residue Thr1604 may be one of the key features of myocardial hypertrophy and disease development.Abbreviations: CaMKII: Ca2+/calmodulin dependent protein kinase II; p-CaMKII: autophosphorylated Ca2+/calmodulin dependent protein kinase II; CaM: calmodulin; AIP: autocamtide-2-related inhibitory peptide; ECC: excitation-contraction coupling; ISO: isoproterenol; BW: body weight; HW: heart weight; LVW: left ventricle weight; HDAC: histone deacetylase; p-HDAC: phosphorylated histone deacetylase; MEF2C: myocyte-specific enhancer factor 2C; ANP: atrial natriuretic peptide; PKC: protein kinase C
format Online
Article
Text
id pubmed-7188351
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-71883512020-05-01 The CaMKII phosphorylation site Thr1604 in the Ca(V)1.2 channel is involved in pathological myocardial hypertrophy in rats Li, Jingyuan Wang, Siqi Zhang, Jie Liu, Yan Zheng, Xi Ding, Fan Sun, Xuefei Zhao, Meimi Hao, Liying Channels (Austin) Research Paper Residue Thr1604 in the Ca(V)1.2 channel is a Ca(2+)/calmodulin dependent protein kinase II (CaMKII) phosphorylation site, and its phosphorylation status maintains the basic activity of the channel. However, the role of Ca(V)1.2 phosphorylation at Thr1604 in myocardial hypertrophy is incompletely understood. Isoproterenol (ISO) was used to induce cardiomyocyte hypertrophy, and autocamtide-2-related inhibitory peptide (AIP) was added as a treatment. Rats in a myocardial hypertrophy development model were subcutaneously injected with ISO for two or three weeks. The heart and left ventricle weights, each of which were normalized to the body weight and cross-sectional area of the myocardial cells, were used to describe the degree of hypertrophy. Protein expression levels were detected by western blotting. CaMKII-induced Ca(V)1.2 (Thr1604) phosphorylation (p-Ca(V)1.2) was assayed by coimmunoprecipitation. The results showed that CaMKII, HDAC, MEF2 C, and atrial natriuretic peptide (ANP) expression was increased in the ISO group and downregulated by AIP treatment in vitro. There was no difference in the expression of these proteins between the ISO 2-week group and the ISO 3-week group in vivo. Ca(V)1.2 channel expression did not change, but p-Ca(V)1.2 expression was increased after ISO stimulation and decreased by AIP. In the rat model, p-Ca(V)1.2 levels and CaMKII activity were much higher in the ISO 3-week group than in the ISO 2-week group. CaMKII-induced Ca(V)1.2 channel phosphorylation at residue Thr1604 may be one of the key features of myocardial hypertrophy and disease development.Abbreviations: CaMKII: Ca2+/calmodulin dependent protein kinase II; p-CaMKII: autophosphorylated Ca2+/calmodulin dependent protein kinase II; CaM: calmodulin; AIP: autocamtide-2-related inhibitory peptide; ECC: excitation-contraction coupling; ISO: isoproterenol; BW: body weight; HW: heart weight; LVW: left ventricle weight; HDAC: histone deacetylase; p-HDAC: phosphorylated histone deacetylase; MEF2C: myocyte-specific enhancer factor 2C; ANP: atrial natriuretic peptide; PKC: protein kinase C Taylor & Francis 2020-04-14 /pmc/articles/PMC7188351/ /pubmed/32290730 http://dx.doi.org/10.1080/19336950.2020.1750189 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Li, Jingyuan
Wang, Siqi
Zhang, Jie
Liu, Yan
Zheng, Xi
Ding, Fan
Sun, Xuefei
Zhao, Meimi
Hao, Liying
The CaMKII phosphorylation site Thr1604 in the Ca(V)1.2 channel is involved in pathological myocardial hypertrophy in rats
title The CaMKII phosphorylation site Thr1604 in the Ca(V)1.2 channel is involved in pathological myocardial hypertrophy in rats
title_full The CaMKII phosphorylation site Thr1604 in the Ca(V)1.2 channel is involved in pathological myocardial hypertrophy in rats
title_fullStr The CaMKII phosphorylation site Thr1604 in the Ca(V)1.2 channel is involved in pathological myocardial hypertrophy in rats
title_full_unstemmed The CaMKII phosphorylation site Thr1604 in the Ca(V)1.2 channel is involved in pathological myocardial hypertrophy in rats
title_short The CaMKII phosphorylation site Thr1604 in the Ca(V)1.2 channel is involved in pathological myocardial hypertrophy in rats
title_sort camkii phosphorylation site thr1604 in the ca(v)1.2 channel is involved in pathological myocardial hypertrophy in rats
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188351/
https://www.ncbi.nlm.nih.gov/pubmed/32290730
http://dx.doi.org/10.1080/19336950.2020.1750189
work_keys_str_mv AT lijingyuan thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT wangsiqi thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT zhangjie thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT liuyan thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT zhengxi thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT dingfan thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT sunxuefei thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT zhaomeimi thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT haoliying thecamkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT lijingyuan camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT wangsiqi camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT zhangjie camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT liuyan camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT zhengxi camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT dingfan camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT sunxuefei camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT zhaomeimi camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats
AT haoliying camkiiphosphorylationsitethr1604inthecav12channelisinvolvedinpathologicalmyocardialhypertrophyinrats